Sanofi to pay $130 million upfront and up to $265 million in potential regulatory milestones to Visirna Therapeutics, a majority-owned subsidiary of ...

EMERYVILLE, CA, USA I July 31, 2025 I 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing ...

TAIPEI, Taiwan I August 1, 2025 I Energenesis Biomedical Co., Ltd. (TWSE: 6657), a clinical-stage biotechnology company focused on cellular energy restoration ...

EAST HANOVER, NJ, USA I July 31, 2025 I Novartis announced today that the US Food and Drug Administration (FDA) has approved a label update for Leqvio® ...

The SGX945 proof of concept pilot study was an open-label study that enrolled 8 patients age 18 years or older with mild to ...

LOS ANGELES, CA, USA I July 30, 2025 I Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company ...

Findings from the TRAILBLAZER-ALZ 2 long-term extension study highlight Kisunla continued to demonstrate slowing of decline, with most participants having ...

Data Showed LEQEMBI Slowed Clinical Decline by 1.75 Points on CDR-SB at Four Years Compared to the Natural History of Alzheimer's Disease ...

CAMBRIDGE, MA, USA I July 30, 2025 I Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission (EC) has granted marketing authorization for the ...

Initiation of additional trial sites and patient enrollment activities ongoing with multiple patients in screening ...

NORTH CHICAGO, IL, USA I July 30, 2025 I AbbVie (NYSE: ABBV) today announced positive topline results from the first of two pivotal studies of the Phase 3 ...

(“Be Bio” or “the Company”), a clinical-stage company pioneering the discovery and development of engineered B Cell Medicines (BCMs), today announced the first participant was treated with BE-101 in ...